source
- Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trialGerman biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
- Vertex renews partnership with Genomics in up to $220 million, four-year extensionVertex Pharmaceuticals has extended its collaboration with sequencing specialist Genomics, signing a new agreement that can be worth up to $220 million. The extension adds four more years to the e…